Trial Profile

Reverse HER2-negative Immune Resistant Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Tretinoin (Primary) ; Antineoplastics; Immune checkpoint protein inhibitors
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms Resilire

Most Recent Events

13 May 2025 Protocol was amended to change the indication from luminal breast cancer to HER-2negative breast cancer.
13 May 2025 Planned End Date changed from 1 Oct 2026 to 1 Oct 2027.
13 May 2025 Planned primary completion date changed from 1 Jul 2026 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com